{
    "case_number": "CAC-UDRP-107444",
    "time_of_filling": "2025-03-31 10:37:35",
    "domain_names": [
        "novartisphamcorp.com",
        "novartispharmcorp.com"
    ],
    "case_administrator": "Olga Dvořáková (Case admin)",
    "complainant": [
        "NOVARTIS AG"
    ],
    "complainant_representative": "Abion GmbH",
    "respondent": [
        "Sotashi Jean (Pharmaceuticals Corp)",
        "Saheed James (Saheed organization)"
    ],
    "respondent_representative": null,
    "factual_background": "<p>FACTS ASSERTED BY THE COMPLAINANT AND NOT CONTESTED BY THE RESPONDENT:<\/p>\n<p>The Complainant is one of the biggest pharmaceutical and healthcare groups in the world. The Complainant&rsquo;s products are manufactured and sold in many countries worldwide, including the United States. The Complainant also states it has an active presence in several countries worldwide, including the United States.<\/p>\n<p>The Complainant provided evidence that it is the registered owner of the Trademarks and several domain names that include the term &ldquo;NOVARTIS&rdquo; such as &lt;novartis.com&gt; since April 2, 1996, and &lt;novartispharma.com&gt; since October 27, 1999.<\/p>\n<p>The Complainant also provided evidence that it has a strong presence online via its social media platforms (Facebook, Twitter, Instagram).<\/p>\n<p>The disputed domain names &lt;novartispharmcorp.com&gt; and &lt;novartisphamcorp.com&gt; were registered on March 6, 2025, and March 17, 2025, respectively.<\/p>",
    "other_legal_proceedings": "<p>The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain names.<\/p>",
    "no_response_filed": "<p>The Complainant contends that the requirements of the Policy have been met and that the disputed domain names should be transferred to it.<\/p>\n<p>No administratively compliant Response has been filed.<\/p>",
    "rights": "<p>The Complainant has, to the satisfaction of the Panel, shown the disputed domain names are identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>",
    "no_rights_or_legitimate_interests": "<p>The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain names (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>",
    "bad_faith": "<p>The Complainant has, to the satisfaction of the Panel, shown the disputed domain names have been registered and are being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>",
    "procedural_factors": "<p>The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>\n<p><\/p>\n<p><strong>Consolidation request: <\/strong>Two respondents were consolidated into a single proceeding, because it appears that these respondents are in fact the same person\/organisation or at least that the two disputed domain names are controlled by the same person\/organisation. &nbsp;The Panel refers, inter alia, to the following factors:<\/p>\n<ul>\n<li>there are clear similarities in the naming pattern or structure of the two disputed domain names: a combined use of the words &ldquo;Novartis&rdquo; (i.e., the Complainant&rsquo;s registered Trademark), &ldquo;pharm&rdquo; or &ldquo;pham&rdquo;(referring to the term &ldquo;pharmaceutical&rdquo;, i.e. the business sector of the Complainant), and &ldquo;corp&rdquo; (referring to the term &ldquo;corporation&rdquo;);<\/li>\n<li>the disputed domain names were registered at close dates:\n<ul>\n<li>&lt;novartispharmcorp.com&gt;: registered on March 6, 2025;<\/li>\n<li>&lt;novartisphamcorp.com&gt;: registered on March 17, 2025;<\/li>\n<\/ul>\n<\/li>\n<li>there are similarities in the contact details of the registrants of the disputed domain names:\n<ul>\n<li>use of proton or protonmail email addresses;<\/li>\n<li>use of non-corporate personal names (&ldquo;Saheed James&rdquo; and &ldquo;Sotashi Jean&rdquo;);<\/li>\n<li>use of addresses and telephone numbers that seem invalid or fabricated:\n<ul>\n<li>&lt;novartispharmcorp.com&gt; uses an address in Oklahoma that appears to be invalid, and a telephone number with the 407 area code that seems to be located in Florida;<\/li>\n<li>&lt;novartisphamcorp.com&gt; uses an address in New Jersey that does not appear to be a normal deliverable mailing address, and a telephone number with the 404 area code that seems to be located in Georgia.<\/li>\n<\/ul>\n<\/li>\n<li>use of the same registrar for the disputed domain names: bot disputed domain names have PDR Ltd. d\/b\/a PublicDomainRegistry.com as a registrar;<\/li>\n<li>both disputed domain names list the same four name servers: &ldquo;ns1.1domainregistry.com&rdquo;, &ldquo;ns2.1domainregistry.com&rdquo;, &ldquo;ns3.1domainregistry.com&rdquo;, and &ldquo;ns4.1domainregistry.com&rdquo;;<\/li>\n<li>both disputed domain names are parked domain names.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>The Respondent has not contested or provided any rebuttal or information regarding the consolidation request made by the Complainant. For the combination of the elements set out above, the Panel is of the opinion that, on the balance of probabilities, the disputed domain names are subject to common control and that the consolidation is fair and equitable to the parties and benefits the procedural efficiency of the case. Therefore, the Panel decides to grant the requested consolidation.<\/p>",
    "decision": "Accepted",
    "panelists": [
        "Bart Van Besien"
    ],
    "date_of_panel_decision": "2025-04-25 00:00:00",
    "informal_english_translation": "<p>The Complainant submitted evidence that it is the owner of the following trademarks:<\/p>\n<p><\/p>\n<ul>\n<li>The international wordmark &ldquo;NOVARTIS&rdquo;, registration number 663765, registered on <strong>July 1, 1996<\/strong>, in classes 1, 2, 3, 4, 5, 7, 8, 9, 10, 14, 16, 17, 20, 22, 28, 29, 30, 31, 32, 40 and 42;<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li>The international wordmark &ldquo;NOVARTIS&rdquo;, registration number 1349878, registered on <strong>November 29, 2016<\/strong>, in classes 9, 10, 41, 42, 44 and 45;<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li>The US wordmark &ldquo;NOVARTIS&rdquo;, registration number 4986124, registered on <strong>June 28, 2016<\/strong>, in classes 5, 6, 18, 44, 46, 51 and 52;<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li>The US combined trademark &ldquo;NOVARTIS&rdquo;, registration number 6990442, registered on <strong>February 28, 2023<\/strong>, in class 5; and<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li>The EU word trademark &ldquo;NOVARTIS&rdquo;, registration number 304857, registered on <strong>June 25, 1999<\/strong>, in classes 1, 5, 9, 10, 29, 30, 31, and 32.<\/li>\n<\/ul>\n<p><\/p>\n<p>Hereinafter the &ldquo;<strong>Trademarks<\/strong>&rdquo;.<\/p>",
    "decision_domains": {
        "novartisphamcorp.com": "TRANSFERRED",
        "novartispharmcorp.com": "TRANSFERRED"
    },
    "panelist": null,
    "panellists_text": null
}